Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 November 2021Website:
http://www.apollomicsinc.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
pre-market | 27 min agoDividend
Analysts recommendations
Institutional Ownership
APLM Latest News
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need
Apollomics (NASDAQ: APLM ) stock is rising higher on Friday as the shares bounce back on recent study results. Those study results cover the “efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion.
Apollomics is a small company with a pipeline of c-Met targeting small molecule TKIs for various cancers. Their lead candidate, Vebreltinib, is in phase 2 trials for NSCLC, GBM, and other solid tumors. They also have a second asset, APL-106, which is a specific E-Selectin antagonist being explored as a therapeutic target in certain types of cancer metastasis.
Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.
Apollomics focuses on therapies for hard-to-treat cancers. The company has nine therapies, with six in clinical trials.
What type of business is Apollomics?
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
What sector is Apollomics in?
Apollomics is in the Healthcare sector
What industry is Apollomics in?
Apollomics is in the Biotechnology industry
What country is Apollomics from?
Apollomics is headquartered in United States
When did Apollomics go public?
Apollomics initial public offering (IPO) was on 26 November 2021
What is Apollomics website?
https://www.apollomicsinc.com
Is Apollomics in the S&P 500?
No, Apollomics is not included in the S&P 500 index
Is Apollomics in the NASDAQ 100?
No, Apollomics is not included in the NASDAQ 100 index
Is Apollomics in the Dow Jones?
No, Apollomics is not included in the Dow Jones index
When does Apollomics report earnings?
Next earnings report date is not announced yet